Recent advances in the management of gastrointestinal stromal tumors

This report focuses mainly on the major reduction of the risk of relapse of gastrointestinal stromal tumor (GIST) treated with imatinib, as identified in the American College of Surgeons Oncology Group (ACOSOG) Z9001 trial. It also focuses on the many unknowns associated with adjuvant imatinib thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Duffaud, Florence, Salas, Sebastien, Huynh, Thanh
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950054/
https://www.ncbi.nlm.nih.gov/pubmed/20948849
http://dx.doi.org/10.3410/M2-36
_version_ 1782187620700258304
author Duffaud, Florence
Salas, Sebastien
Huynh, Thanh
author_facet Duffaud, Florence
Salas, Sebastien
Huynh, Thanh
author_sort Duffaud, Florence
collection PubMed
description This report focuses mainly on the major reduction of the risk of relapse of gastrointestinal stromal tumor (GIST) treated with imatinib, as identified in the American College of Surgeons Oncology Group (ACOSOG) Z9001 trial. It also focuses on the many unknowns associated with adjuvant imatinib therapy despite approvals by the US Food and Drug Administration and the European Medicines Agency, and on a new marker for the diagnosis of GIST.
format Text
id pubmed-2950054
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medicine Reports Ltd
record_format MEDLINE/PubMed
spelling pubmed-29500542010-10-14 Recent advances in the management of gastrointestinal stromal tumors Duffaud, Florence Salas, Sebastien Huynh, Thanh F1000 Med Rep Review Article This report focuses mainly on the major reduction of the risk of relapse of gastrointestinal stromal tumor (GIST) treated with imatinib, as identified in the American College of Surgeons Oncology Group (ACOSOG) Z9001 trial. It also focuses on the many unknowns associated with adjuvant imatinib therapy despite approvals by the US Food and Drug Administration and the European Medicines Agency, and on a new marker for the diagnosis of GIST. Medicine Reports Ltd 2010-05-11 /pmc/articles/PMC2950054/ /pubmed/20948849 http://dx.doi.org/10.3410/M2-36 Text en © 2010 Medicine Reports Ltd
spellingShingle Review Article
Duffaud, Florence
Salas, Sebastien
Huynh, Thanh
Recent advances in the management of gastrointestinal stromal tumors
title Recent advances in the management of gastrointestinal stromal tumors
title_full Recent advances in the management of gastrointestinal stromal tumors
title_fullStr Recent advances in the management of gastrointestinal stromal tumors
title_full_unstemmed Recent advances in the management of gastrointestinal stromal tumors
title_short Recent advances in the management of gastrointestinal stromal tumors
title_sort recent advances in the management of gastrointestinal stromal tumors
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950054/
https://www.ncbi.nlm.nih.gov/pubmed/20948849
http://dx.doi.org/10.3410/M2-36
work_keys_str_mv AT duffaudflorence recentadvancesinthemanagementofgastrointestinalstromaltumors
AT salassebastien recentadvancesinthemanagementofgastrointestinalstromaltumors
AT huynhthanh recentadvancesinthemanagementofgastrointestinalstromaltumors

Ejemplares similares